muscleblind like splicing regulator 1Genealiases: EXP · MBNL
Q-omics provides the consensus-scored MBNL1 profile across patient tissues and cancer cell-line models. MBNL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MBNL1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, MBNL1 protein abundance shows 24,868 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where MBNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBNL1 survival associations across molecular data types. MBNL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBNL1 RNA expression–survival associations across cancer types. High MBNL1 expression shows unfavorable associations in KIRP, KICH and LGG, but favorable associations in SKCM, HNSC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MBNL1 RNA expression.
This table summarizes MBNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MBNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBNL1 shows lower tumor expression in COAD, LUAD, BLCA and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher MBNL1 RNA expression in tumor versus normal tissue (log2 FC = +0.875, t-test p < 0.001).
This table shows molecular features associated with MBNL1 in patient tissues and cancer cell lines. In patient samples, MBNL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MBNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
